Phosphatidylserine Supplementation Improves Metabolic Liver Disease and Glycemic Control in the Presence of Suppressed Oxidative Glucose Metabolism

The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes is increasing. We show that dietary phosphatidylserine supplementation reduces hepatic lipid accumulation, inflammation, and liver fibrosis while further improving blood glucose control and insulin sensitivity in mice with MASH and insulin resistance. Improvements in glycemic control are present despite suppression of glycolysis, glucose oxidation, and glycogen breakdown in liver, skeletal muscle, and/or adipose tissue. In contrast, oxidative lipid metabolism and overall mitochondrial function are enhanced in skeletal muscle.